N-Acetylserotonin (NAS) is a naturally occurring chemical intermediate in biosynthesis of melatonin. Previous studies have shown that NAS has different brain distribution patterns from those of serotonin and melatonin, suggesting that NAS might have functions other than as a precursor or metabolite of melatonin. Indeed, several studies have now shown that NAS may play an important role in mood regulation and may have antidepressant activity. Additional studies have shown that NAS stimulates proliferation of neuroprogenitor cells and prevents some of the negative effects of sleep deprivation. It is believed that the antidepressant and neurotrophic actions of NAS are due at least in part to the capability on this molecule to activate the TrkB receptor in a brain-derived neurotrophic factor-independent manner. Emerging evidence also indicates that NAS and its derivatives have neuroprotective properties and protect retinal photoreceptor cells from light-induced degeneration. In this review, the authors discuss the literature about this exciting and underappreciated molecule.
Review N-Acetylserotonin (NAS) is synthesized in the mammalian pineal gland and retina. Until very recently, NAS was believed to be just an intermediate in the biosynthetic pathway of melatonin with no or very limited biological function of its own. NAS is produced from serotonin by the enzyme arylalkylamine N-acetyltransferase (AANAT) and is converted to melatonin by acetylserotonin O-methyltransferase (ASMT; or hydroxyindole O-methyltransferase [HIOMT]) ( Figure 1 ). Although NAS is predominantly synthesized in the pineal gland and retina, a series of studies have also provided experimental evidence that NAS and AANAT activity are present in the hippocampus, the olfactory bulb, the spinal cord, and the cerebellum (Paul and others 1974; Psarakis and others 1982; Gaudet and others 1991; Chae and others 1999) . These earlier findings have been supported by more recent studies using RT-PCR to analyze Aanat mRNA expression (Uz and others 2002) . The experimental observation that NAS may reside in specific brain areas separate from melatonin and serotonin suggests that NAS may have a role in the central nervous system distinct from that of being a precursor for melatonin.
As with melatonin, NAS shows a clear daily/circadian variation in its level. In the pineal gland, the levels of NAS start to surge three to four hours after the onset of darkness at night and begin to decrease before the onset of light in the morning (Chattoraj and others 2009 ). The rhythmic synthesis in the pineal gland is controlled by the circadian clock located in the suprachiasmatic nucleus (SCN) of the hypothalamus. At night, the SCN sends signals to the pineal gland via sympathetic neurons that release norepinephrine (NE), thus activating adrenergic receptors to increase intracellular Ca 2+ and cAMP with the consequent phosphorylation of the cAMP response element (CRE) binding protein (CREB) (Klein and others 1997) . Phosphorylated CREB activates Aanat gene expression via CREs in the Aanat promoter others 1997, 1999; Figure 2) . cAMP also stimulates the phosphorylation of AANAT protein, which promotes its association with 14-3-3 proteins, activating the enzyme and protecting it from degradation (Ganguly and others 2001; Pozdeyev and others 2006; Figure 2) . The changes in the activity of AANAT are responsible for the variation in NAS (and melatonin) levels (Klein and others 1997) . The levels of NAS are tightly controlled by light at the level of AANAT activity. Exposure to light rapidly (within minutes) reduces AANAT activity by reducing cAMP, resulting in dephosphorylation and proteasomal proteolysis of the AANAT protein (Klein and Weller 1972; Klein and others 1978; Gastel and others 1998; Fukuhara and others 2001; Pozdeyev and others 2006) . The rapid destruction of the AANAT protein results in an almost immediate decrease in pineal levels of NAS and melatonin ( Figure 2 ).
An important aspect of NAS biology is the identification of the receptors that are involved in modulation of its biological functions. Previous studies have shown that NAS has some activity on the membrane G-proteincoupled melatonin receptors (MT 1 and MT 2 ) (Nonno and others 1999), but the affinity is several orders of magnitude lower than that for melatonin. Other studies have suggested that the putative MT3 binding site has a higher affinity for NAS than for melatonin. Thus, it has been suggested that MT3 may act as an NAS receptor (Nosjean and others 2000) . A recent study has shown that NAS may be a ligand for TrkB receptor, the cognate receptor for brain-derived neurotrophic factor (BDNF). NAS robustly activates the TrkB receptor in a BDNF-and MT3 receptor-independent manner (Jang and others 2010).
NAS Displays Antidepressant-like Activity
A number of early studies suggested that NAS may be an endogenous antidepressant molecule. For example, exogenous administration of NAS decreases immobility in the mouse tail suspension test (Prakhie and Oxenkrug 1998) and chronic administration (three weeks) of the antidepressant fluoxetine induces a fivefold increase in the levels of Aanat mRNA and, presumably, NAS in the hippocampus (Uz and Manev 1999) . Additionally, clorgyline, a selective monoamine oxidase A (MAO-A) inhibitor with antidepressant-like activity, increases (5-fold) rat pineal melatonin and NAS content, and decreases 5-HIAA (MAO-oxidized metabolite) level by 80%, whereas deprenyl, a selective MAO-B inhibitor, does not change the content of melatonin or other pineal indoles (Oxenkrug and others 1985) . As we have previously discussed, NAS activates TrkB receptors (Jang and others 2010), and several investigations have indicated that activation of TrkB receptors may be a common mechanism of antidepressant drug action (e.g., Rantamäki and others 2007) . The activation of TrkB by acute administration of some, but not all antidepressant drugs may involve NAS. For example, the selective serotonin reuptake inhibitors (SSRI) fluoxetine and citalopram and the tricyclic antidepressant desipramine robustly stimulate TrkB activation in hippocampus of mice that synthesize NAS (C3H/f +/+ mice) as well as in C57BL/6 mice (Jang and others 2010), which have a mutation in AANAT that prevents the synthesis of appreciable amounts of NAS or melatonin (Roseboom and others 1998) . In contrast, the MAO-A inhibitor clorgyline, which increases serotonin levels, stimulates TrkB activation in the C3H/f +/+ mice but not in the C57BL/6 mice (Jang and others 2010). Interestingly, clorgyline only activates TrkB in C3H/f +/+ mice when administered at night in the dark, when AANAT is active; in contrast, clorgyline is ineffective at activating TrkB when admisitered to mice exposed to light, which inactivates AANAT. These findings suggest that clorgyline-induced TrkB activation is attributable to increased levels serotonin and the subsequent conversion to NAS in darkness. Because deprenyl, an MAO-B inhibitor does not stimulate serotonin or NAS levels, it is unable to trigger TrkB activation whether the light is on or off. However, the SSRI and tricyclic antidepressants markedly activate TrkB regardless of dark or light. This result combined with the observation that these drugs stimulate TrkB phosphorylation in hippocampus of C57BL/6J mice with defective AANAT indicates that NAS is not a major effector in TrkB activation by acute administration of these agents. Clorgyline increases both melatonin and NAS levels in rat pineal glands (Oxenkrug and others 1985) . Further experiments have shown that intraperitoneal administration of NAS one hour before testing significantly decreases the duration of immobility in the forced swim test as compared to saline control (Jang and others 2010). By contrast, melatonin has little effect. This finding is consistent with a previous report that NAS, but not melatonin, reduces duration of immobility in the tail-suspension test (Prakhie and Oxenkrug 1998) . Interestingly, pretreatment with a specific inhibitor of TrkB abolished the antidepressant-like behavioral effect of NAS, suggesting that the antidepressantlike effect of NAS is mediated through TrkB activation (Jang and others 2010) .
A growing body of evidence suggests that BDNFmediated TrkB signaling is both sufficient and necessary for antidepressant-like behaviors in rodents. However, it appears that the action of NAS is independent from BDNF since administration of exogenous NAS, but not of melatonin, activates TrkB in mice lacking BDNF (Jang and others 2010). However, these results do not exclude the possibility that NAS and BDNF might additively or synergistically regulate each other's neurotrophic activity on TrkB. Interestingly, it has been observed that TrkB activation in C3H/f +/+ mice follow a daily/circadian pattern that is consistent with the oscillation of endogenous NAS, and this effect is absent in C57BL/6J mice that lack endogenous NAS. Furthermore, the observations that TrkB is activated by clorgyline in C3H/f +/+ mice, but not in C57BL/6J mice, and is prevented by light exposure, which inhibits NAS synthesis, further indicate that the synthesis of endogenous NAS induced by clorgyline accounts for this effect (Jang and others 2010). These results provide compelling evidence that the molecular mechanism underlying the antidepressant role of NAS involves activation of TrkB receptors and suggest that the chronic treatment with fluoxetine, which increases Aanat transcription, leads to an increase in NAS, activation of TrkB, enhanced synaptic plasticity, neurogenesis, and synaptogenesis (Li and others 2008) . In conclusion, activation of TrkB by NAS appears to provide a molecular mechanism for the antidepressant-like action of of the melatonin precursor (Jang and others 2010) .
Agomelatine, which is structurally homologous to melatonin, is a novel antidepressant with agonist activity at melatonin receptors (MT 1 and MT 2 ), and antagonistic effects at the 5HT 2c serotonin receptor (San and Arranz 2008) . Agomelatine produces strong effects on circadian sleep phase disturbances, improving time to sleep onset 
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The Neuroscientist 18 (6) and quality of sleep (Spadoni and others 2011) . It has been shown to be superior to placebo and similar to existing antidepressants, as demonstrated by short-term clinical trials and one relapse prevention trial (Hickie and Rogers 2011) . Agomelatine appears to be well tolerated, without sexual or cardiac adverse effects, weight gain, or discontinuation syndromes that are frequently observed with the monoaminergic antidepressants (Demyttenaere 2011) . Since melatonin itself does not provoke TrkB receptor activation in primary neurons or animals, conceivably, agomelatine might exert its antidepressant effect through its demethylated metabolite that may mimic NAS and activate TrkB receptors in the brain.
NAS and Neuroprotection
NAS has antioxidant properties, and it has been suggested that it may be useful in protection from oxidative stressrelated disorders (Oxenkrug 2005) , such as Alzheimer disease, Parkinsonism, and age-related macular degeneration. The antioxidant effects of NAS may involve both direct chemical interactions and receptor-mediated mechanisms. NAS appears to be protective against excitotoxic neuronal injury by activating TrkB receptors. In TrkB F616A knockin mice, administration of kainic acid induces apoptosis in brain neurons, as indicated by activation of caspase 3 (Jang and others 2010). Pretreatment with NAS but not melatonin inhibits caspase 3 activation by kainic acid, and this effect is blocked by the specific TrkB F616A inhibitor 1NMMPP1.
Several derivatives of NAS have recently been developed (Shen and others 2012). One of these, N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperideine-3-carboximide (HIOC), selectively activates TrkB with greater potency than NAS and has a significantly longer biological half-life than NAS after systemic administration. The compound can pass the blood-brain and blood-retinal barriers when administered systemically and reduces kainic acid-induced neuronal cell death in a TrkB-dependent manner.
BDNF, an endogenous ligand of TrkB, has neuroprotective effects in the retina, decreasing ganglion cell loss from optic nerve damage (Mansour-Robaey and others 1994) and photoreceptor loss in bright light-induced retinal degeneration (LaVail and others 1998). However, BDNF must be injected directly into the eye to be effective, as it does not cross the blood-retinal barrier. Interestingly, systemic administration of HIOC mitigates bright lightinduced photoreceptor degeneration (Shen and others 2012), suggesting that this compound may be useful in the treatment of retinal degenerative diseases.
NAS may be an endogenous neuroprotectant. C57BL/6 mice, which are genetically deficient in NAS, lose ~50% of their retinal ganglion cells by 18 months of age (Danias and others 2003) . In contrast, C3H/f +/+ mice, which make NAS, show no age-related decline in retinal ganglion cells (Baba and others 2009). While it is tempting to attribute this difference in cell survival to NAS, caution is warranted as many genetic differences exist between these two strains of mice.
Sleep, Neurogenesis, and NAS
Sleep is a naturally recurring state characterized by a reduced sensory activity and is divided into two main types: rapid eye movement (REM) and non-rapid eye movement (NREM) sleep. The purposes and mechanisms of sleep are only partially understood and are the subject of intense research. In humans, as well as in laboratory rodents, the temporal organization of sleep during the 24-hour daily cycle ultimately results from the activity of two interacting time-keeping mechanisms in the central nervous system: endogenous circadian rhythmicity and sleep-wake homeostasis. Sleep-wake homeostasis refers to the increase in propensity to fall asleep and increased sleep duration and intensity that occur following extended waking. The sleep "homeostat," also referred to as "process S," is often represented as an hourglass mechanism relating the amount and intensity of sleep to the duration of prior wakefulness (Figure 3 ; Borbély and Achermann 1999). In both humans and rodents, slow-wave activity (SWA or "delta power"; i.e., EEG power density in the low frequency range < 4 Hz), an index that quantifies the depth of NREM sleep or "sleep intensity," is the primary marker of sleep-wake homeostasis (Borbély and Achermann 1999) . Chronic partial sleep loss in humans appears to have cumulative effects on process S (Carskadon and Dement 1979; Dinges and others 1997) .
Chronic partial sleep loss, whether due to voluntary sleep curtailment, sleep disorders, or medical illnesses, is pervasive throughout our society. "Normal" sleep duration has decreased from approximately nine hours in 1910 to an average of seven hours in 2000 (Johnson 2000) . Today, many individuals are in bed only five to six hours per night on a chronic basis (Jean-Louis and others 2000). Until a few years ago, the dogma was that sleep is only important for brain function (Benington and Heller 1995) . Now, accumulating experimental evidence indicates that sleep loss induces significant alterations in metabolism, cardiovascular function, mood, and cognitive performance (Neckelmann and others 2007; Spiegel and others 2009) . Neurogenesis is the process by which neurons are generated during the development of the central nervous system. Until very recently it was believed that neurogenesis in mammals could only occur during early development; today, we know that neurogenesis can continue in a few brain regions of adults (Ming and Song 2005) . Neuronal progenitor cell (NPC) proliferation is an early event of neurogenesis, a process by which new neurons are continuously generated and incorporated into the nervous system. New neurons are continually generated in the dentate gyrus of the hippocampus and in the subventricular zone of the adult brain (Eriksson and others 1998, Gould and others 1999) . It has been shown that aging and stress can suppress neurogenesis, but enriched environmental conditions, voluntary exercise such as running, as well as antidepressants can positively modulate hippocampal neurogenesis (Ming and Song 2005; Lledo and others 2006; Zhao and others 2008; Ma and others 2009) .
Mounting evidence also suggests that sleep may contribute to hippocampal functions by promoting neurogenesis. Total sleep deprivation for 96 hours reduces cell proliferation and neurogenesis in the dentate gyrus of the hippocampus in adult rats (Guzman-Marin and others 2005), and sleep deprivation impairs hippocampusdependent learning and abolishes learning-induced neurogenesis (Hairston and others 2005) . Initially, it was proposed that stress and glucocorticoids were the major factor in reduction of neurogenesis (Mirescu and others 2006) . However, additional study reveals that adrenalectomized animals also show a significant reduction (more than 50%) in the number of proliferating cells with respect to control, thus suggesting that sleep deprivation reduces hippocampal neurogenesis at least in part by a glucocorticoid-independent mechanism (Guzman Marin and others 2007; Mueller and others 2011). Interestingly, the effect of sleep seems to be associated with changes in REM sleep (Guzman-Marin and others 2008). The reduction in neurogenesis induced by sleep fragmentation is likely to underlie the delayed changes in cognitive function often observed after sleep deprivation (Sportiche and others 2010) . Finally, contrary to what has been reported from extended sleep deprivation, acute sleep deprivation (12 hours) may upregulate hippocampal neurogenesis (Grassi-Zucconi and others 2006; Junek and others 2010). The mechanisms by which sleep deprivation affects neurogenesis are still unknown.
Our recent study suggests that NAS is critical for promoting an early event of neurogenesis in dentate gyrus (Sompol and others 2011) . Mice treated with NAS showed a significant increase (about 30%) in NPCs that correlates with an increase in TrkB phosphorylation in the hippocampus (Sompol and others 2011) . The increase in NCPs in the dentate gyrus was inhibited by blockage of the TrkB receptors (Jang and others 2010; Sompol and others 2011).
A series of investigations have suggested that alterations of circadian rhythms may affect neurogenesis since many aspects of hippocampal physiology show significant circadian fluctuation (Chaudhury and Colwell 2002; Chaudhury and others 2005) . Moreover, it has been reported that clock gene expression or clock-controlled gene expression is rhythmic in the hippocampus (Fukuhara and others 2004; Jilg and others 2010) and that the clock gene Period 2 is expressed in NPC (Borgs and others 2009) . Additional studies indicate that cell proliferation may vary with the time of day (Guzman-Marin and others 2007; Tamai and others 2008; Gilhooley and others 2011) . Our data indicate that the effect of NAS on NCP is independent from the time of day since exogenous NAS was equally effective in inducing NPC proliferation in both the active and sleeping phases in mice (Sompol and others 2011) . Interestingly, sleep deprivation significantly diminishes NPC proliferation in C57BL/6 mice but not in C3H mice, suggesting that in C3H mice endogenously generated NAS may reduce the negative consequences of sleep deprivation (Sompol and others 2011) .
Recently, it has been suggested that melatonin may contribute to neurogenesis (Rennie and others 2009; Ramírez-Rodríguez and others 2009, 2011; Manda and Reiter 2010) . Melatonin has been reported to promote sleep in many animal models and in humans (Brzezinski and others 2005; Buscemi and others 2006; Ochoa-Sanchez and others 2011) and administration of exogenous melatonin increases neurogenesis in the hippocampus (Rennie and others 2009; Ramírez-Rodríguez and others 2009, 2011; Manda and Reiter 2010) . Our recent studies indicate that administration of exogenous melatonin does not increase the number of proliferating NPCs even with three weeks of treatment (Jang and others 2010; Sompol and others 2011). However, it is possible that melatonin may still promote neuronal survival once NPC proliferation has occurred (Ramírez-Rodríguez and others 2011). Figure 3 . The current model for sleep regulation involves two processes: a sleep-dependent process (Process S, blue line) and a circadian process (Process C, red line). Sleep propensity (Process S) increases during the wake time and rapidly decrease during sleep. The circadian clock (Process C) opposes sleep propensity by sending an alerting signal that begins to rise before the awakening and continues to increase into the late part of the wake period. Therefore, the sleepwake cycle is determined by the coincident and opposing actions of these two processes (adapted from Borbély and Ackermann 1999).
Nevertheless, the data available in the literature suggest that NAS and melatonin have different physiological functions, and NAS acts as a potent neuroprotective agent through the neurotrophic receptor TrkB, whereas melatonin exerts its biological effects through melatonin receptors or as an antioxidant. Further studies using melatonin receptor knockout mice are required to fully understand the specific roles played by melatonin and NAS in neuroprotection and neurogenesis.
An important aspect of the action of NAS is the mechanisms by which NAS can induce neurogenesis. A large amount of published data indicates that BDNF modulates neuronal survival and may also affect neurogenesis via TrkB signaling. We have shown that NAS can activate TrkB and its associated signaling cascades and this is the likely mechanism whereby NAS promotes neurogenesis and neuronal survival (Jang and others 2010; Figure 4) .
Sleep deprivation is a common characteristic of modern society and therefore understanding the negative effects of sleep loss on health and well being is an important step to prevent disease states associated with it and to develop effective treatment that may prevent the negative consequences of sleep deprivation. Emerging experimental evidence suggests that NAS, and its derivatives, may represent a new treatment that may prevent the decrease in cognitive function often observed in sleep-deprived individuals.
Is NAS Involved in the Regulation of Circadian Rhythms?
In mammals, circadian rhythms are driven by a master pacemaker located in the SCN of the hypothalamus. The SCN is necessary for expression of most sustained circadian rhythms. Destruction of these cells eliminates most circadian rhythms of physiology and behavior, demonstrating the SCN's ability to dictate circadian periodicity (Herzog and Tosini 2001) . The SCN is also responsible for the photic entrainment of circadian rhythms by receiving a direct projection from a specialized class of retinal ganglion cells (Paul and others 2009) . Previous studies have also implicated TrkB in the photic regulation of SCN function; TrkB receptors are expressed in the SCN (Liang and others 1998; and blockade of TrkB signaling in the SCN inhibits the photic phase-shift (Liang and others 2000) . Finally, it has been shown that heterozygous TrkB mutant mice have significantly smaller phase shifts in response to light at night, compared to wild type controls (Allen and others 2005) . Our new data demonstrating that NAS can activate TrkB receptors (Jang and others 2010) together with observation that NAS may be synthesized within the SCN (Hamada and others 1999) raises the intriguing hypothesis that NAS, together or independently from BDNF, may also play a role in modulating the entrainment of circadian rhythms. Finally, it is also possible to speculate that NAS may serve an endogenous neuroprotective role in the SCN in order to provide an extra protection for the neurons located in this important key brain structure.
Conclusions
NAS has recently been found to play unexpected roles in neuronal cell biology by activating TrkB signaling. NAS may contribute to neurogenesis and neuronal survival, circadian rhythms and sleep, affective function, and hippocampus-dependent cognitive function. NAS derivatives may be useful as neuroprotectant drugs for the treatment of retinal degenerations and, perhaps, other neurodegenerative disorders.
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